Latest Articles

Publication Date
Incidental Primary Ovarian Squamous Cell Carcinoma Arising in Endometriosis Presenting As Adenomyosis-Related Abnormal Uterine Bleeding.

Adenomyosis often coexists with endometriosis, which primarily involves the ovary and can lead to endometriosis‑associated ovarian cancers, most commonly endometrioid and clear‑cell carcinomas. Ovarian squamous cell carcinoma (OSCC) arising in …

Published: Aug. 22, 2025, midnight
Immunotherapy plus chemotherapy approved for endometrial cancer - The Pharmaceutical Journal

Immunotherapy plus chemotherapy approved for endometrial cancer The Pharmaceutical Journal

Published: Aug. 7, 2025, 2:48 p.m.
Breakthrough treatment combines immunotherapy and chemotherapy - National Health Executive

Breakthrough treatment combines immunotherapy and chemotherapy National Health Executive

Published: Aug. 7, 2025, 8:48 a.m.
Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights - Cureus

Lenvatinib Plus Pembrolizumab Versus Chemotherapy in Advanced Endometrial Cancer: Efficacy and Safety Insights Cureus

Published: July 30, 2025, 7:21 a.m.
Gastric ectopic pancreatic ductal adenocarcinoma coexisted with endometriosis mimick advanced disease: a case report and literature review.

Ectopic pancreas (EP) is most commonly located in the upper gastrointestinal tract, particularly in the stomach. Malignant transformation of EP is exceptionally rare, and due to its very low incidence, …

Published: July 24, 2025, midnight
NXF1 suppresses progression of endometrial cancer by interacting with the SRSF3 to regulate SP4 splicing.

Conventional treatments for advanced endometriosis often have limited efficacy due to chemotherapy resistance, recurrence, and metastasis. This study analyzed clinical specimens to investigate the role of NXF1 in endometrial cancer …

Published: July 22, 2025, midnight
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer - Medical Xpress

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer Medical Xpress

Published: June 2, 2025, 6:20 p.m.
Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise - Newswise

Adding immunotherapy to standard chemotherapy extends quality of life for patients with advanced endometrial cancer | Newswise Newswise

Published: June 2, 2025, 2:25 p.m.
Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer - OncLive

Real-World Analysis Informs Future Directions for Evaluating Dostarlimab/Chemotherapy in Advanced Endometrial Cancer OncLive

Published: May 28, 2025, 2:28 p.m.
Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!